| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
|
N Engl J Med
|
2006
|
18.25
|
|
2
|
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
|
N Engl J Med
|
2013
|
11.34
|
|
3
|
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
|
N Engl J Med
|
2014
|
10.54
|
|
4
|
Clinical end points in coronary stent trials: a case for standardized definitions.
|
Circulation
|
2007
|
10.31
|
|
5
|
Coronary intervention for persistent occlusion after myocardial infarction.
|
N Engl J Med
|
2006
|
8.74
|
|
6
|
Genetic determinants of response to clopidogrel and cardiovascular events.
|
N Engl J Med
|
2008
|
8.39
|
|
7
|
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology.
|
Eur Heart J
|
2008
|
8.20
|
|
8
|
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.
|
JAMA
|
2004
|
7.32
|
|
9
|
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
|
JAMA
|
2010
|
6.29
|
|
10
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
|
N Engl J Med
|
2006
|
5.07
|
|
11
|
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2008
|
5.03
|
|
12
|
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.
|
JAMA
|
2006
|
5.00
|
|
13
|
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
|
Lancet
|
2010
|
4.72
|
|
14
|
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern.
|
Circulation
|
2007
|
4.24
|
|
15
|
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
|
N Engl J Med
|
2013
|
4.16
|
|
16
|
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
|
Lancet
|
2010
|
3.55
|
|
17
|
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
|
Lancet
|
2008
|
3.36
|
|
18
|
Darapladib for preventing ischemic events in stable coronary heart disease.
|
N Engl J Med
|
2014
|
2.90
|
|
19
|
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
|
J Am Coll Cardiol
|
2007
|
2.56
|
|
20
|
Metformin use and mortality among patients with diabetes and atherothrombosis.
|
Arch Intern Med
|
2010
|
2.52
|
|
21
|
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
|
Eur Heart J
|
2007
|
2.31
|
|
22
|
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
|
Circulation
|
2010
|
2.27
|
|
23
|
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events.
|
Chest
|
2004
|
2.19
|
|
24
|
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis.
|
Am Heart J
|
2008
|
2.09
|
|
25
|
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
|
Circulation
|
2008
|
2.05
|
|
26
|
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.
|
Eur Heart J
|
2012
|
1.95
|
|
27
|
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
|
Circulation
|
2012
|
1.84
|
|
28
|
Patients with peripheral arterial disease in the CHARISMA trial.
|
Eur Heart J
|
2009
|
1.80
|
|
29
|
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.
|
Circulation
|
2009
|
1.77
|
|
30
|
MRI of acute myocarditis: a comprehensive approach based on various imaging sequences.
|
Chest
|
2002
|
1.64
|
|
31
|
Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events.
|
Heart
|
2010
|
1.53
|
|
32
|
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation].
|
G Ital Cardiol (Rome)
|
2009
|
1.52
|
|
33
|
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
|
Am Heart J
|
2011
|
1.47
|
|
34
|
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design.
|
Am Heart J
|
2006
|
1.45
|
|
35
|
Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF.
|
Europace
|
2013
|
1.41
|
|
36
|
Differentiating acute myocardial infarction from myocarditis: diagnostic value of early- and delayed-perfusion cardiac MR imaging.
|
Radiology
|
2005
|
1.33
|
|
37
|
One-year costs in patients with a history of or at risk for atherothrombosis in the United States.
|
Circ Cardiovasc Qual Outcomes
|
2008
|
1.21
|
|
38
|
Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
|
Atherosclerosis
|
2008
|
1.16
|
|
39
|
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
|
Am J Cardiol
|
2010
|
1.13
|
|
40
|
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
|
Crit Pathw Cardiol
|
2009
|
1.11
|
|
41
|
Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countries.
|
Circulation
|
2010
|
1.08
|
|
42
|
The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry.
|
Stroke
|
2008
|
1.05
|
|
43
|
Incomplete resolution of ST-segment elevation is a marker of transient microcirculatory dysfunction after stenting for acute myocardial infarction.
|
Circulation
|
2003
|
1.05
|
|
44
|
ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation.
|
Rev Esp Cardiol
|
2009
|
0.97
|
|
45
|
Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events.
|
Arch Intern Med
|
2009
|
0.97
|
|
46
|
Risk factor profile and management of cerebrovascular patients in the REACH Registry.
|
Cerebrovasc Dis
|
2008
|
0.95
|
|
47
|
Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
|
Am Heart J
|
2009
|
0.90
|
|
48
|
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
|
Circulation
|
2008
|
0.90
|
|
49
|
Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan.
|
Circ J
|
2007
|
0.88
|
|
50
|
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry.
|
Am Heart J
|
2009
|
0.88
|
|
51
|
Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction.
|
Thromb Haemost
|
2007
|
0.88
|
|
52
|
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
|
JAMA
|
2002
|
0.87
|
|
53
|
Two-year vascular event rates in patients with symptomatic cerebrovascular disease: the REACH registry.
|
Cerebrovasc Dis
|
2011
|
0.87
|
|
54
|
Comparison of acute coronary syndrome in patients receiving versus not receiving chronic dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry).
|
Am J Cardiol
|
2011
|
0.86
|
|
55
|
Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry.
|
J Neurol Sci
|
2009
|
0.85
|
|
56
|
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
|
Am J Cardiol
|
2009
|
0.85
|
|
57
|
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry).
|
Am J Cardiol
|
2007
|
0.85
|
|
58
|
Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry.
|
Crit Pathw Cardiol
|
2009
|
0.84
|
|
59
|
Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry.
|
Nat Clin Pract Cardiovasc Med
|
2008
|
0.84
|
|
60
|
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
|
J Am Coll Cardiol
|
2009
|
0.83
|
|
61
|
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
|
J Am Coll Cardiol
|
2009
|
0.83
|
|
62
|
The paradox of cholesterol and stroke.
|
Lancet
|
2007
|
0.83
|
|
63
|
Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
|
Circulation
|
2010
|
0.82
|
|
64
|
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial.
|
Eur Heart J
|
2006
|
0.82
|
|
65
|
The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).
|
Can J Cardiol
|
2011
|
0.81
|
|
66
|
Management and outcomes following an acute coronary event in patients with chronic heart failure 1999-2007.
|
Eur J Heart Fail
|
2012
|
0.81
|
|
67
|
Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF survey.
|
Clin Cardiol
|
2013
|
0.81
|
|
68
|
Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
|
Int J Cardiol
|
2012
|
0.81
|
|
69
|
An evidence-based score to detect prevalent peripheral artery disease (PAD).
|
Vasc Med
|
2012
|
0.80
|
|
70
|
Does preventive PCI work?
|
N Engl J Med
|
2007
|
0.80
|
|
71
|
Cardiac diffusion-weighted MR imaging in recent, subacute, and chronic myocardial infarction: a pilot study.
|
J Magn Reson Imaging
|
2013
|
0.80
|
|
72
|
Cardiovascular risk profiles and outcomes of Chinese living inside and outside China.
|
Eur J Cardiovasc Prev Rehabil
|
2010
|
0.80
|
|
73
|
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
|
Am J Cardiol
|
2011
|
0.79
|
|
74
|
Clinical presentation and management of stable coronary artery disease: insights from the international prospective CLARIFY registry - results from the Greek national cohort.
|
Hellenic J Cardiol
|
2014
|
0.79
|
|
75
|
A meta-analysis that misses the mark.
|
J Am Coll Cardiol
|
2008
|
0.79
|
|
76
|
One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.
|
Can J Cardiol
|
2010
|
0.79
|
|
77
|
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.
|
Am Heart J
|
2009
|
0.79
|
|
78
|
Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry.
|
Stroke
|
2006
|
0.78
|
|
79
|
Impact of smoking on the incidence and survival of cardiogenic shock complicating acute myocardial infarction treated with reperfusion therapy.
|
Am J Cardiol
|
2002
|
0.77
|
|
80
|
Atherothrombotic disease, traditional risk factors, and 4-year mortality in a Latin American population: the REACH Registry.
|
Clin Cardiol
|
2012
|
0.77
|
|
81
|
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
|
Am Heart J
|
2005
|
0.76
|
|
82
|
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy.
|
Am Heart J
|
2013
|
0.76
|
|
83
|
Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT).
|
EuroIntervention
|
2009
|
0.75
|
|
84
|
β-Blocker use for patients with or at risk for coronary artery disease--reply.
|
JAMA
|
2013
|
0.75
|
|
85
|
Devices to protect against embolization during primary angioplasty for ST-segment elevation myocardial infarction: the good, the bad and the ugly.
|
Eur Heart J
|
2008
|
0.75
|
|
86
|
Reply: Pulse Pressure and Cardiovascular Death.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
87
|
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis.
|
Crit Pathw Cardiol
|
2010
|
0.75
|
|
88
|
News from the European Society of Cardiology congress in Vienna, August 30 to September 3, 2003.
|
J Am Coll Cardiol
|
2004
|
0.75
|
|
89
|
[Restenosis estimation at the clinical level: methodologic and angiographic aspects].
|
Pathol Biol (Paris)
|
2004
|
0.75
|
|
90
|
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. 2004.
|
Chest
|
2009
|
0.75
|
|
91
|
Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs.
|
Heart
|
2011
|
0.75
|
|
92
|
Towards evidence-based percutaneous coronary intervention: the René Laënnec lecture in clinical cardiology.
|
Eur Heart J
|
2012
|
0.75
|